

**Amendments to the Specification:**

Please replace the paragraph on page 17, lines 17-32 of the specification with the following amended paragraph:

The present invention not only includes the monoclonal antibodies referred to above but also includes the novel hybridoma cell lines which produce these antibodies. More specifically, the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-3890 produces monoclonal antibody 120A-270, the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-2809 produces monoclonal antibody 115B-151, the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-2806 produces monoclonal antibody 117-289, the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-2808 produces monoclonal antibody 103-350, the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-2807 produces monoclonal antibody 108-394, and the cell line ~~ATCC HB \_\_\_\_\_~~ PTA-2810 produces monoclonal antibody 115B-303. The cell lines producing the antibodies, with the exception of PTA-3890, were deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110 under the terms of the Budapest Treaty on December 13, 2000 and were accorded the ATCC numbers noted above. Cell line PTA-3890 was deposited with the American Type Culture Collection on December 4, 2001.